Delcath Systems Inc's (NASDAQ:DCTH) single-institution retrospective study data on CHEMOSAT Hepatic Delivery System for liver dominant metastatic uveal melanoma (mUM) were published in the journal Melanoma Research.
- 41 of 81 (50.6%) patients had received other treatments, either systemic or liver-directed, before percutaneous hepatic perfusion (PHP) treatment. 250 PHP procedures were performed in 81 patients.
- The Company's PHP system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- The PHP system is being developed under the tradename, Hepzato Kit.
- Related: Delcath Systems Reveals Initial Survival Data From Ocular Melanoma Trial.
- The analysis demonstrated a hepatic disease control rate of 88.9% (72/81), a hepatic response rate of 66.7%, and an overall response rate of 60.5%.
- After a median follow-up of 12.9 months, median overall progression-free survival (PFS) and median overall survival (OS) were 8.4 and 14.9 months, respectively.
- Treatment-emergent adverse events of Grade 3 or 4 occurred in 23 patients, anemia observed in 11 patients (13.3%), and thrombocytopenia in 10 patients (12%).
- There were no fatal treatment-related adverse events.
- Price Action: DCTH shares closed at $6.99 on Thursday.
